<<
>>

the analysis of survival rate depending on scheme PVT

At patients from both groups differences in survival rate SVO depending on scheme PVT (the Appendix 1, tab have been taped. 8 and 9).

At patients HGV receiving rekombinantnyj INF a-2b 3 times in ned + Lamivudin (scheme PVT 1), the cumulative share of survival SVO at the moment of time at a stage of 12 and 24 months has made 0,600±0,155 and 0,200±0,126 accordingly, further in group has been taped active replikatsija a virus.

At the patients receiving rekombinantnyj INF a-2b daily + Lamivudin (scheme PVT 2), a cumulative share of survival SVO at the moment of time at stages of 12 and 36 months has made 0,636±0,145, 0,188±0,098 accordingly, further all patients had active replikatsiju a virus (fig. 25).

Fig. 25. Function of attainig the age SVO at patients HGV depending on scheme PVT

Average time of attainig the age SVO for patients with at PVT (1) has made 8,000±2,567, for patients with PVT (2) - 7,579±2,464 (tab. 125).

Table 125

Averages and medians of time of attainig the age SVO at patients HGV in dependence

From scheme PVT

HG The scheme

PVT

Average! 1 Median
Estimation The item an error 95 % the confidential

Interval

Estimation The item

Error

95 % a confidential interval
The bottom

Border

The top

Border

The bottom border The top border
IN 1 8,000 2,567 2,969 13,031 0,000 8,000
2 7,579 2,464 2,749 12,409 0,000 7,579

At patients HGS receiving rekombinantnyj INF a-2b 3 times in ned + (scheme PVT 1), a cumulative share of survival SVO at the moment of time at a stage

12 and 24 months has made 0,300±0,145 and 0,200±0,126 accordingly, further at a stage 48 mes indicator CENSORED is noted. At the patients receiving rekombinantnyj pegelirovannyj INF a-2b + ribavirin (the scheme

PVT 2), at all finished observation at a stage 48 mes indicator CENSORED ^^^) is noted.

Fig. 26. Function of attainig the age SVO at patients HGS depending on the scheme

PVT

Average time of attainig the age SVO for patients with at PVT (1) has made 24,358±2,254, for patients with PVT (2) - 6,000±2,462 (tab. 126).

Table 126

Averages and medians of time of attainig the age SVO at patients HGS depending on scheme PVT

HG The scheme

PVT

Sredneea Median
Estimation The item

Error

95 % a confidential interval Estimation The item an error 95 % a confidential interval
The bottom

Border

The top

Border

The bottom border The top border
WITH 1 24,358 2,254 0,000 48,000 0,000 24,358
2 6,000 2,462 6,000 24,000 0,000 6,000

Thus, as a whole survival rate SVO at HGS above, than at HGV. Some factors influence this indicator at patients with HGV. prediktorom the female is positive. At girls in 5 times more time of conservation SVO (proof remission). At initially low virus load at the patients who have reached SVO, stable remission remained more longly more, than in 2 times. The nationality of the patient, as well as frequency rate of introduction INF and - 2b short action did not influence duration of conservation SVO.

At girls with HGS also proof remission was observed almost in 2 times more longly, than at boys. At patients with HGS the high virus load was positive preditktorom conservations of stable remission. The choice of the combined therapy pegelirovannym INF a-2 and ribavirinom has allowed to keep proof remission to all patients who have finished observation.

<< | >>
Scientific source Dmitriev Tatyana Gennadevna. CHRONIC VIRUS HEPATITISES At CHILDREN And TEENAGERS In REGION GIPERENDEMICHNOM. The PROGRAM of PERFECTION of RENDERING of the MEDIKO-SOCIAL HELP. The dissertation on competition of a scientific degree of the doctor of medical sciences. Yakutsk - 2014. 2014

Ñêà÷àòü îðèãèíàë èñòî÷íèêà

Other medical related information the analysis of survival rate depending on scheme PVT:

  1. INTRODUCTION
  2. 2.2. Research methods
  3. the analysis of survival rate depending on scheme PVT